Medigene AG
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its lead product includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications. The company also develop… Read more
Market Cap & Net Worth: Medigene AG (MDG1)
Medigene AG (XETRA:MDG1) has a market capitalization of $2.02 Million (€1.97 Million) as of March 19, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #34344 globally and #3941 in its home market, demonstrating a -33.08% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medigene AG's stock price €0.13 by its total outstanding shares 14737600 (14.74 Million).
Medigene AG Market Cap History: 2015 to 2025
Medigene AG's market capitalization history from 2015 to 2025. Data shows change from $249.93 Million to $2.02 Million (-37.01% CAGR).
Medigene AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medigene AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
7.26x
Medigene AG's market cap is 7.26 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $249.93 Million | $6.81 Million | -$13.00 Million | 36.71x | N/A |
| 2016 | $341.90 Million | $9.75 Million | -$9.49 Million | 35.07x | N/A |
| 2017 | $365.74 Million | $11.38 Million | -$13.57 Million | 32.15x | N/A |
| 2018 | $212.03 Million | $7.75 Million | -$17.05 Million | 27.35x | N/A |
| 2019 | $114.92 Million | $10.63 Million | -$19.96 Million | 10.81x | N/A |
| 2020 | $101.13 Million | $8.75 Million | -$28.88 Million | 11.56x | N/A |
| 2021 | $82.31 Million | $10.46 Million | -$9.98 Million | 7.87x | N/A |
| 2022 | $58.04 Million | $31.25 Million | -$8.33 Million | 1.86x | N/A |
| 2023 | $43.81 Million | $6.03 Million | -$16.18 Million | 7.26x | N/A |
Competitor Companies of MDG1 by Market Capitalization
Companies near Medigene AG in the global market cap rankings as of March 19, 2026.
Key companies related to Medigene AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Medigene AG Historical Marketcap From 2015 to 2025
Between 2015 and today, Medigene AG's market cap moved from $249.93 Million to $ 2.02 Million, with a yearly change of -37.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €2.02 Million | -87.04% |
| 2024 | €15.58 Million | -64.44% |
| 2023 | €43.81 Million | -24.50% |
| 2022 | €58.04 Million | -29.49% |
| 2021 | €82.31 Million | -18.61% |
| 2020 | €101.13 Million | -12.00% |
| 2019 | €114.92 Million | -45.80% |
| 2018 | €212.03 Million | -42.03% |
| 2017 | €365.74 Million | +6.97% |
| 2016 | €341.90 Million | +36.80% |
| 2015 | €249.93 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Medigene AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.02 Million USD |
| MoneyControl | $2.02 Million USD |
| MarketWatch | $2.02 Million USD |
| marketcap.company | $2.02 Million USD |
| Reuters | $2.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.